• Register
  • Login

European Journal of Molecular & Clinical Medicine

  1. Home
  2. “INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM): A BOON TO FUTURE”

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

“INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM): A BOON TO FUTURE”

    Author

    • Dr. Shyamkumar Sirsam, Dr. Payal Bobade, Dr. Rohit Dimbar, Dr. Rajat Sharma , Dr. Dhanshree Rajurkar
,

Document Type : Research Article

  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

Background: Postpartum anemia imposes a disproportionately substantial disease burden during a critical period of maternal-infant interaction. Postpartum anemia requires prevention and treatment not only for that particular period but also to ensure good health with enough iron stores at the start of the next pregnancy. Among various parenteral iron preparations, single-dose intravenous (FCM) ferric carboxymaltose is more effective to cure anemia.
Material & Methods:
This was an observational prospective interventional study in 120 anemic postnatal women in Government Medical College, Akola- Maharashtra. Patients with Hb <10 grams were assigned to this study and were given intravenous FCM. Data were collected and statistical analysis was performed. Treatment potency was assessed through repeat hemoglobin (Hb) and ferritin titers which indicate the iron (Fe) stores. Drug safety was assessed by the evaluation of drug reactions.
Results :
A significant rise in Hb, MCV, and ferritin levels was observed after 1 week and 1 month after receiving Inj.FCM. The mean change in the hemoglobin levels were 0.845 and 2.405 on day 7 and at day 28 respectively. Mean changes in the MCV levels were 3.06 and 6.42 on day 7 and on day 28 respectively. The mean change in the Sr. Ferritin levels was 102.56 ng / ml on day 28. This means the change in the Sr. Ferritin level was statistically significant with a ‘P’ value < 0.0001.
Conclusion:
Intravenous ferric carboxymaltose is an efficacious and safe drug to treat postpartum anemia in women of reproductive age.

Keywords

  • Postpartum anemia
  • IV FCM
  • hemoglobin
  • XML
  • PDF 423.2 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
    • Article View: 50
    • PDF Download: 137
European Journal of Molecular & Clinical Medicine
Volume 9, Issue 7
September 2022
Page 3256-3264
Files
  • XML
  • PDF 423.2 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
Statistics
  • Article View: 50
  • PDF Download: 137

APA

Dr. Dhanshree Rajurkar, D. S. S. D. P. B. D. R. D. D. R. S. ,. (2022). “INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM): A BOON TO FUTURE”. European Journal of Molecular & Clinical Medicine, 9(7), 3256-3264.

MLA

Dr. Shyamkumar Sirsam, Dr. Payal Bobade, Dr. Rohit Dimbar, Dr. Rajat Sharma , Dr. Dhanshree Rajurkar. "“INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM): A BOON TO FUTURE”". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 3256-3264.

HARVARD

Dr. Dhanshree Rajurkar, D. S. S. D. P. B. D. R. D. D. R. S. ,. (2022). '“INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM): A BOON TO FUTURE”', European Journal of Molecular & Clinical Medicine, 9(7), pp. 3256-3264.

VANCOUVER

Dr. Dhanshree Rajurkar, D. S. S. D. P. B. D. R. D. D. R. S. ,. “INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM): A BOON TO FUTURE”. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 3256-3264.

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Glossary
  • Sitemap

News

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

© Journal Management System. Powered by ejournalplus